Accumulating evidence suggests chronic inflammation of metabolic tissues plays a causal role in obesity-induced insulin resistance. Yet, how specific endothelial factors exert impacts in metabolic tissues remains undefined. Bone morphogenetic protein (BMP)-binding endothelial regulator (BMPER) adapts endothelial cells to inflammatory stress in diverse organ microenvironments.Here we demonstrate BMPER is a driver of insulin sensitivity. Inducible knockout (iKO) of BMPER causes hyperinsulinemia, glucose intolerance and insulin resistance without increasing inflammation in metabolic tissues. Interestingly, BMPER can directly activate insulin signaling, which requires its internalization and interaction with Niemann-Pick C1 (NPC1), an integral membrane protein that transports intracellular cholesterol. These results suggest the endocrine function of the vascular endothelium maintains glucose homeostasis. Of potential clinical significance, the delivery of BMPER recombinant protein or its overexpression significantly alleviates insulin resistance and hyperglycemia in high-fat diet (HFD)-fed mice and Lepr db/db (db/db) diabetic mice. We conclude that BMPER exhibits therapeutic potential for the treatment of diabetes.Diabetes mellitus (DM) is a group of metabolic diseases characterized by chronic hyperglycemia and impaired carbohydrates, lipids and protein metabolism resulting from defects in insulin secretion, insulin action or both. More than 100 million U.S. adults are now living with diabetes or prediabetes, a condition that if not treated often leads to type 2 diabetes mellitus (T2DM) within five years 1 . T2DM is the most common form of DM, accounting for 90% to 95% of all diabetic patients and is expected to increase to 693 million by 2045 2 . T2DM is associated with an increased risk of micro-and macrovascular complications, such as diabetic nephropathy, neuropathy, retinopathy and coronary artery disease, which impose profound impacts on the quality of life and health care resources. Current management of diabetes includes lifestyle intervention, routine blood glucose monitoring and pharmacological therapy. However, high costs, variable efficiency and tolerability are important barriers to the use of these pharmacological treatments.